West Pharmaceutical Services (WST) Non-Current Debt (2016 - 2025)
Historic Non-Current Debt for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $202.8 million.
- West Pharmaceutical Services' Non-Current Debt rose 9.87% to $202.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $202.8 million, marking a year-over-year increase of 9.87%. This contributed to the annual value of $202.8 million for FY2025, which is 9.87% up from last year.
- Latest data reveals that West Pharmaceutical Services reported Non-Current Debt of $202.8 million as of Q4 2025, which was up 9.87% from $202.7 million recorded in Q3 2025.
- West Pharmaceutical Services' 5-year Non-Current Debt high stood at $252.3 million for Q1 2021, and its period low was $72.8 million during Q4 2023.
- Over the past 5 years, West Pharmaceutical Services' median Non-Current Debt value was $204.2 million (recorded in 2023), while the average stood at $187.5 million.
- Per our database at Business Quant, West Pharmaceutical Services' Non-Current Debt crashed by 6477.99% in 2023 and then surged by 17829.67% in 2024.
- Over the past 5 years, West Pharmaceutical Services' Non-Current Debt (Quarter) stood at $208.8 million in 2021, then fell by 1.01% to $206.7 million in 2022, then tumbled by 64.78% to $72.8 million in 2023, then soared by 178.3% to $202.6 million in 2024, then grew by 0.1% to $202.8 million in 2025.
- Its last three reported values are $202.8 million in Q4 2025, $202.7 million for Q3 2025, and $202.6 million during Q2 2025.